Semaglutide vs. Tirzepatide: Which GLP-1 Medication Is Right for You?

What Are GLP-1 Medications?

GLP-1 receptor agonists are a class of medications that mimic a hormone your gut naturally releases after eating. They signal your brain that you’re full, slow stomach emptying, and help regulate blood sugar. Originally developed for type 2 diabetes, they’ve become the most talked-about weight loss tools in modern medicine.

Two names dominate the conversation: semaglutide (sold as Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (sold as Mounjaro for diabetes, Zepbound for weight loss). Both work — but they’re not identical, and understanding the differences can help you make a smarter decision with your provider.

How They Work Differently

This is the key distinction. Semaglutide targets one receptor — the GLP-1 receptor. Tirzepatide is a dual agonist, targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.

Think of it this way: semaglutide turns one metabolic dial, tirzepatide turns two. That second dial — GIP — appears to enhance the appetite-suppressing and fat-burning effects beyond what GLP-1 alone can achieve. This is likely why tirzepatide produces greater average weight loss in clinical trials.

Weight Loss Results: What the Research Shows

In the SURMOUNT-1 trial, participants on tirzepatide lost an average of 20.9% of body weight over 72 weeks at the highest dose. In the STEP 1 trial, semaglutide participants lost an average of 14.9% of body weight.

That’s a meaningful difference — roughly 6 extra percentage points. For a 200-pound person, that’s the difference between losing 30 pounds vs. 42 pounds on average.

However, averages don’t tell the full story. Some people respond exceptionally well to semaglutide. Others plateau on tirzepatide. Genetics, baseline metabolic health, lifestyle factors, and adherence all play significant roles.

Side Effects: What to Expect

Both medications share similar side effect profiles because they act on overlapping pathways. The most common side effects include:

• Nausea — the most frequently reported, especially during dose escalation
• Vomiting — less common, usually tied to nausea
• Diarrhea or constipation — digestive system adjustments are normal early on
• Decreased appetite — this is actually the intended effect, not a side effect per se
• Fatigue — often temporary as your body adjusts

At our practice, we find that slow, gradual dose escalation dramatically reduces side effects for most patients. Rushing to the highest dose is rarely necessary and often counterproductive.

More serious but rare risks include pancreatitis, gallbladder issues, and — based on animal studies — a theoretical risk of thyroid C-cell tumors (which is why both are contraindicated in people with a personal or family history of medullary thyroid cancer or MEN2).

Cost and Insurance Coverage

Cost is a real barrier. Without insurance, both medications run $900–$1,400 per month at retail pharmacy prices. Coverage varies significantly:

• Diabetes diagnosis: Ozempic and Mounjaro are more likely to be covered
• Weight loss only: Wegovy and Zepbound coverage is improving but still inconsistent
• Manufacturer savings cards: Both companies offer programs that can reduce cost significantly for commercially insured patients
• Compounded versions: FDA-approved compounding pharmacies have offered lower-cost alternatives during shortages, though supply is now more stable

Who Is a Good Candidate?

Both medications are FDA-approved for adults with:

• A BMI of 30 or higher (obesity), or
• A BMI of 27 or higher (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol

They are NOT appropriate for people who are pregnant, have a personal or family history of certain thyroid cancers, or have had pancreatitis. A thorough health history review with a qualified provider is essential before starting either medication.

Which Should You Choose?

There’s no universal answer, but here’s a practical framework:

• Choose tirzepatide if you want maximum weight loss potential, you have insulin resistance or type 2 diabetes, or you haven’t responded well to semaglutide in the past
• Choose semaglutide if cost is a primary concern (it’s been available longer and may have better generic/biosimilar options soon), you’ve responded well previously, or tirzepatide isn’t covered by your insurance
• The best choice is always the one you’ll stick with — consistency matters more than which drug you’re on

The Functional Medicine Difference

At Fundamental Wellness of Nebraska, we don’t prescribe GLP-1 medications in isolation. We use them as part of a comprehensive weight loss strategy that includes:

• Hormone optimization (thyroid, estrogen, testosterone, cortisol)
• Nutritional and metabolic assessment
• Gut health evaluation
• Body composition monitoring — not just the scale
• Strategies to preserve muscle mass during rapid weight loss

Weight loss medications work best when the underlying metabolic picture is addressed. That’s the functional medicine approach — and it’s what separates lasting results from the yo-yo cycle.

NP Jenna Witt has helped patients in Norfolk, Nebraska and across Northeast Nebraska achieve meaningful, sustainable weight loss using GLP-1 therapy combined with personalized metabolic care. If you’re ready to explore whether semaglutide or tirzepatide is right for you, book a consultation today.